Federal Project Grant Award Summary

The Defense Health Agency awarded The Geneva Foundation a $999,766 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2026, through August 31, 2029. The project, "Accelerating Personalized T-Cell Receptor Immunotherapy for Microsatellite-Stable Colorectal Cancer with a Multimodal Prediction Model," supports advanced biomedical research to develop and validate innovative cancer immunotherapy approaches. This three-year initiative aligns with the Defense Health Agency's mission to transform health care for Service Members through investigator-initiated research addressing conditions affecting the military population, including translational oncology research in colorectal cancer.

The award funds research activities to be conducted at The Geneva Foundation's Tacoma, Washington facility. As a 501(c)(3) nonprofit research organization with extensive experience in defense and health biomedical research, Geneva will leverage its clinical research infrastructure and oncology expertise to advance personalized immunotherapy development and the supporting prediction model. This project represents the program's standard investment in three- to four-year research initiatives within the $100,000 to $20 million award range, following the two-tier peer and programmatic review process that evaluates technical merit and military relevance.